Show simple item record

dc.contributor.authorAmeratunga, Men_US
dc.contributor.authorKipps, Een_US
dc.contributor.authorOkines, AFCen_US
dc.contributor.authorLopez, JSen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2018-11-14T09:10:48Z
dc.date.issued2019-01-01en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30224338en_US
dc.identifier1078-0432.CCR-18-1999en_US
dc.identifier.citationClin Cancer Res, 2019, 25 (1), pp. 21 - 28en_US
dc.identifier.issn1078-0432en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2924
dc.identifier.doi10.1158/1078-0432.CCR-18-1999en_US
dc.description.abstractDysregulation of cell division resulting in aberrant cell proliferation is a key hallmark of cancer, making it a rational and important target for innovative anticancer drug development. Three selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are FDA and European Medicines Agency (EMA) approved for hormone receptor-positive/HER2-negative advanced breast cancer. A major emerging appreciation is that these inhibitors not only are cytostatic, but also play critical roles in the interaction between tumor cells and the host immune response. However, to trigger an effective immune response, lymphocytes must also proliferate. This review aims to assimilate our emerging understanding on the role of CDK4/6 inhibitors in cell-cycle control, as well as their biological effect on T cells and other key immune cells, and the confluence of preclinical evidence of augmentation of anticancer immunity by these drugs. We aim to provide a framework for understanding the role of the cell cycle in anticancer immunity, discussing ongoing clinical trials evaluating this concept and challenges for developing rational combinations with immunotherapy.en_US
dc.format.extent21 - 28en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleTo Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-09-12en_US
rioxxterms.versionofrecord10.1158/1078-0432.CCR-18-1999en_US
rioxxterms.licenseref.startdate2019-01-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClin Cancer Resen_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate)
pubs.publication-statusPublisheden_US
pubs.volume25en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine (de Bono Prostate)en_US
dc.contributor.icrauthorLopez, Juanitaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record